ClinicalTrials.gg
Active, not recruitingNCT06975722COLOR UCUpdated Nov 2, 2026

A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis

A Phase 2 interventional study of SAR442970 and Placebo in Ulcerative Colitis, sponsored by Sanofi. Active, not recruiting at 69 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Updated Nov 2, 2026Now Active, not recruitingEnrollment updated+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Colitis, Ulcerative by Sanofi — 3 open to participants now, 6 under way, 2 of them phase 3. Colitis, Ulcerative · Sanofi.

Enrollment
6th of 12
105 · median 87
Started
2025
with 2 others
Phase 2
8 of 12
none open now
Registered
8th of 12
by date

Among the 12 studies in Colitis, Ulcerative by Sanofi, this one is the 6th largest by enrollment, is one of 3 that started in 2025, is one of 8 in phase 2, and was the 8th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

3 of the 12 studies in Colitis, Ulcerative by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Colitis, Ulcerative by Sanofi, or all of them as a file.
02

Study summary

This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Ulcerative Colitis. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Ulcerative Colitis. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 2, 2026. See what changed

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  • Male or female participants aged 18 to 75 years inclusive, at the time of signing the
  • Participants who have had clinical evidence of active UC for ≥3 months before screening and confirmed by endoscopy during the screening period
  • Must have active moderate-to-severe UC at screening as defined by a modified Mayo Score (mMS) of 5 to 9 (without the Physician Global Assessment (PGA), with a minimum Rectal Bleeding (RB) subscore ≥1, a minimum Stool Frequency (SF) subscore ≥1, mMES ≥2 confirmed by central reader and a minimum disease extent of 15 cm from the anal verge
  • Must have received prior treatment for UC (either "a" or "b" below or combination of both):

    1. History of inadequate response to, loss of response to or intolerance to standard treatment with any of the following compounds: amino-salicylates, , methotrexate, azathioprine, or 6-mercaptopurine, or history of corticosteroid dependence (defined as an inability to successfully taper corticosteroids without recurrence of UC) AND history of no prior exposure to approved Advanced Therapies (ATs), such as a biologic agent used to treat UC or advanced small molecules used to treat UC
    2. History of inadequate response to, loss of response to or intolerance to treatment with ≥1 approved AT such as a biologic agent used to treat UC or advanced small molecules used to treat UC
  • use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies

Exclusion criteria

Exclusion Criteria:

  • Participants are excluded from the study if any of the following criteria apply:
  • Participants with active Crohn's Disease (CD), indeterminate colitis or microscopic colitis
  • Participants with fecal sample positive for culture/ova for aerobic pathogens or positive for Clostridium difficile B toxin in stools
  • Participant with ostomy or ileoanal pouch, prior colectomy or anticipated colectomy during their participation in the study
  • Participants with the following ongoing known complications of UC: fulminant disease, toxic megacolon or colonic dysplasia except for adenoma
  • Participants with intestinal failure or short bowel syndrome requiring Total Parenteral Nutrition
  • History of recurrent or recent serious infection within 4 weeks of screening, or infection(s) requiring hospitalization or treatment with IV anti-infectives within 30 days prior to baseline, or infections(s) requiring oral anti-infectives within 14 days prior to baseline, except as required as part of an anti-Tuberculosis (TB) regimen
  • Known history of or suspected significant current .
  • History or solid organ transplant or splenectomy
  • History of moderate to severe congestive heart failure (New York Health Association Class III or IV), or recent cerebrovascular accident.
  • History of demyelinating disease (including myelitis), family history of demyelinating disease, or neurologic symptoms suggestive of demyelinating disease
  • Participants with a history of or lymphoproliferative disease other than adequately treated localized carcinoma in situ of the cervix or nonmetastatic squamous cell carcinoma, or nonmetastatic basal cell carcinoma of the skin
  • Participants with a diagnosis of inflammatory conditions other than UC (including but not limited to systemic lupus erythematosus, systemic sclerosis, myositis, rheumatoid arthritis, primary biliary cirrhosis, multiple sclerosis, Behcet's disease, sarcoidosis, etc.)
  • History of (HIV) infection or positive HIV serology at Screening
  • History of Interstitial Lung Disease
  • Participants with any of the following results at Screening:

    • Positive surface antigen (HBs Ag) or,
    • Positive total Hepatitis B core antibody (anti-HBcAB)
    • Positive Virus (HCV) antibody confirmed by positive HCV Ribonucleic Acid (RNA) (participants with HCV antibody (HCVAb) and negative HCV RNA may be included).
  • Screening laboratory and other analyses showing abnormal results
  • History of any other condition which, in the opinion of the Investigator, would put the participant at risk by participation in the protocol

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    SAR442970 Dose Regimen A

    Participants will receive SAR442970 dose regimen A

    Drug: SAR442970

  • Experimental
    SAR442970 Dose Regimen B

    Participants will receive SAR442970 dose regimen B

    Drug: SAR442970 · Drug: Placebo

  • Placebo comparator
    Placebo

    Participants will receive SAR442970-matching placebo

    Drug: Placebo

Interventions

  • Route of administration: Subcutaneous

    Also known as: brivekimig

  • DrugPlacebo

    Route of administration: Subcutaneous

06

What researchers measure

Primary outcomes

  1. Proportion of participants who achieve clinical remission at the end of Week 16 by modified Mayo Score (mMS)

    Clinical remission is defined as a mMS of 0 to 2, including Stool Frequency (SF) subscore of 0 or 1, Rectal Bleeding (RB) subscore of 0 and modified Mayo Endoscopic (mMES) of 0 or 1 confirmed by central reader (score of 1 does not include friability)

    Time frame: At Week 16

Secondary outcomes

  1. Proportion of participants who achieve endoscopic improvement at Week 16

    Endoscopic improvement is defined as an mMES of 0 or 1 (where 1 does not include friability).

    Time frame: At Week 16

  2. Proportion of participants who achieve endoscopic response at Week 16

    Endoscopic response is defined as an mMES decrease of at least 1.

    Time frame: At Week 16

  3. Proportion of participants who achieve endoscopic remission at Week 16

    Endoscopic remission is defined as an mMES of 0, confirmed by central reader

    Time frame: At Week 16

  4. Proportion of participants who achieve endoscopic improvement at Week 52

    Endoscopic improvement is defined as an mMES of 0 or 1 (where 1 does not include friability). The mMES ranges from 0 to 3 with higher scores indicating greater disease severity.

    Time frame: At Week 52

  5. Proportion of participants who achieve clinical remission by total Mayo Score (MS) at Week 16

    Clinical remission (total MS) is defined as total MS ≤2 with no individual subscore \>1.

    Time frame: At Week 16

  6. Proportion of participants who achieve clinical response at Week 16 by total MS

    Clinical response by total MS is defined as a decrease from baseline in the total MS of ≥3 points and at least 30% reduction from baseline, and a decrease in the RB subscore of ≥1 or an absolute RB subscore of 0 or 1.

    Time frame: At Week 16

  7. Proportion of participants who achieve clinical response at Week 16 by mMS

    Clinical response by mMS is defined as a decrease from baseline in the mMS of ≥2 points and an improvement of ≥30% from baseline plus a decrease in RB subscore ≥1 or an absolute RB subscore ≤1.

    Time frame: At Week 16

  8. Proportion of participants who achieve clinical remission at Week 52 by mMS

    Clinical remission is defined as an mMS score of 0 to 2, including SF subscore of 0 or 1, RB subscore of 0, and mMES of 0 or 1 (score of 1 does not include friability).

    Time frame: At Week 52

  9. Change from baseline in Inflammatory Bowel Disease Questionnaire (IBDQ)

    This captures the patient's experience of inflammatory bowel disease (IBD) on 4 domains of functioning and well-being: bowel and systemic symptoms and emotional and social function. The Inflammatory Bowel Disease Questionnaire (IBDQ) is a 32-item instrument assessing health-related quality of life in IBD patients across four dimensions: bowel symptoms (10 items), systemic symptoms (5 items), emotional function (12 items), and social function (5 items). Each question evaluates experiences over the previous two weeks on a 7-point Likert scale from 1 (worst) to 7 (best). The total score ranges from 32 to 224, with higher scores indicating better quality of life. Both domain-specific and overall scores can be calculated.

    Time frame: From Baseline to Week 16

  10. Serum brivekimig concentrations

    Time frame: Up to end of study (approximately 164 weeks)

  11. Incidence of Anti-drug Antibodies (ADAs)

    Time frame: Up to end of study (approximately 164 weeks)

  12. Number (percentage) of participants with any Treatment Emergent Adverse Events (TEAEs) during the Induction and Maintenance treatment periods

    Time frame: From start of induction period to Week 52

  13. Number (percentage) of participants with any TEAEs during the Long-term Extension (LTE) period

    Time frame: From Week 52 (start of LTE period) up to end of the study (approximately 164 weeks)

07

Study locations

69 sites
  • Investigational Site Number: 8400027
    Fairhope, Alabama 36532, United States
  • Investigational Site Number: 8400009
    Escondido, California 92025, United States
  • Investigational Site Number: 8400006
    Lancaster, California 93534, United States
  • Investigational Site Number: 8400025
    Thousand Oaks, California 91360, United States
  • Investigational Site Number: 8400024
    Jacksonville, Florida 32258, United States
  • Investigational Site Number: 8400030
    Kissimmee, Florida 347441, United States
  • Investigational Site Number: 8400003
    Lighthouse PT, Florida 33064, United States
  • Investigational Site Number: 8400001
    Miami, Florida 33134, United States
  • Investigational Site Number: 8400011
    Miami, Florida 33136, United States
  • Investigational Site Number: 8400010
    Palmetto Bay, Florida 33176, United States
  • Investigational Site Number: 8400019
    Tampa, Florida 33609, United States
  • Investigational Site Number: 8400018
    Marietta, Georgia 30060, United States
  • Investigational Site Number: 8400005
    Iowa City, Iowa 52242, United States
  • Investigational Site Number: 8400028
    Kansas City, Kansas 66160, United States
  • Investigational Site Number: 8400017
    Boston, Massachusetts 02115, United States
  • Investigational Site Number: 8400012
    Wyoming, Michigan 49519, United States
  • Investigational Site Number: 8400014
    St Louis, Missouri 63110, United States
  • Investigational Site Number: 8400021
    New York, New York 10029, United States
  • Investigational Site Number: 8400029
    Queens Village, New York 11428, United States
  • Investigational Site Number: 8400023
    Houston, Texas 77030, United States
  • Investigational Site Number: 8400007
    Ogden, Utah 84405, United States
  • Investigational Site Number: 0360003
    Brisbane, Queensland 4101, Australia
  • Investigational Site Number: 0360001
    Clayton, Victoria 3168, Australia
  • Investigational Site Number: 360002
    Murdoch, 6150, Australia
  • Investigational Site Number: 1560004
    Huizhou, Ghangdong 516001, China
  • Investigational Site Number: 1560005
    Guangzhou, Guangdong 510655, China
  • Investigational Site Number: 1560002
    Nanjing, Jiangsu 210029, China
  • Investigational Site Number: 1560008
    Suzhou, Jiangsu 215006, China
  • Investigational Site Number: 1560003
    Wuxi, Jiangsu 214023, China
  • Investigational Site Number: 1560009
    Shanghai, Shanghai Municipality 200025, China
  • Investigational Site Number: 1560001
    Hangzhou, 310016, China
  • Investigational Site Number: 1560007
    Ningbo, 315010, China
  • Investigational Site Number: 2030001
    Brno, JM 61500, Czechia
  • Investigational Site Number: 2030002
    Slaný, 27401, Czechia
  • Investigational Site Number: 2500002
    Lille, 59037, France
  • Investigational Site Number: 2500007
    Montpellier, 34090, France
  • Investigational Site Number: 2500006
    Nice, 6200, France
  • Investigational Site Number: 2500005
    Pierre-Bénite, 69495, France
  • Investigational Site Number: 2500001
    Saint-Priest-en-Jarez, 42270, France
  • Investigational Site Number: 2760001
    Minden, Northwest 32423, Germany
  • Investigational Site Number: 2760005
    Kiel, Schleswig-Holstein 24105, Germany
  • Investigational Site Number: 2760003
    Ulm, 89081, Germany
  • Investigational Site Number: 3480003
    Budapest, 1066, Hungary
  • Investigational Site Number: 3480002
    Budapest, 1088, Hungary
  • Investigational Site Number: 3480001
    Vác, 2600, Hungary
  • Investigational Site Number: 3920002
    Kashiwa, Chiba 277-0871, Japan
  • Investigational Site Number: 3920006
    Ōita, Oita Prefecture 870-0033, Japan
  • Investigational Site Number: 3920005
    Hamamatsu, 431-3192, Japan
  • Investigational Site Number: 3920003
    Hirosaki, 036-8545, Japan
  • Investigational Site Number: 3920001
    Morioka, 020-8505, Japan
  • Investigational Site Number: 3920004
    Nishinomiya, 663-8501, Japan
  • Investigational Site Number: 4980001
    Chisinau, 2025, Moldova
  • Investigational Site Number: 6160006
    Wroclaw, Lower Silesian Voivodeship 53-149, Poland
  • Investigational Site Number: 6160002
    Bydgoszcz, 85-229, Poland
  • Investigational Site Number: 6160009
    Chojnice, 89-600, Poland
  • Investigational Site Number: 6160007
    Katowice, 40-748, Poland
  • Investigational Site Number: 6160005
    Sopot, 81-756, Poland
  • Investigational Site Number: 6160008
    Tychy, 43-100, Poland
  • Investigational Site Number: 6160004
    Warsaw, 00-189, Poland
  • Investigational Site Number: 6160003
    Warsaw, 04-501, Poland
  • Investigational Site Number: 6160001
    Wroclaw, 52-210, Poland
  • Investigational Site Number: 7240003
    Barcelona, 8022, Spain
  • Investigational Site Number: 7240001
    Las Palmas de Gran Canaria, 35010, Spain
  • Investigational Site Number: 7240002
    Madrid, 28046, Spain
  • Investigational Site Number: 8260002
    Northwich, CHW CW9 7LS, United Kingdom
  • Investigational Site Number: 8260003
    Bury, BL9 7TD, United Kingdom
  • Investigational Site Number: 8260005
    Cambridge, CB2 0QQ, United Kingdom
  • Investigational Site Number: 8260001
    London, E11 1NR, United Kingdom
  • Investigational Site Number: 8260004
    London, SE1 7EH, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's planned 17 months is below that.

Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2025
First posted
May 16, 2025
StartActual
Jul 7, 2025
Primary completionEst.
Dec 17, 2026
CompletionEst.
Oct 17, 2029
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 2, 2026
Sites
7 sites added, 5 sites removed
Show 7 added (2 France, 2 United States, 1 Australia, 1 Spain, 1 United Kingdom)
  • Investigational Site Number: 2500007 · Montpellier, France
  • Investigational Site Number: 8400027 · Fairhope, United States
  • Investigational Site Number: 8400028 · Kansas City, United States
  • Investigational Site Number: 360002 · Murdoch, Australia
  • Investigational Site Number: 2500006 · Nice, France
  • Investigational Site Number: 7240003 · Barcelona, Spain
  • Investigational Site Number: 8260005 · Cambridge, United Kingdom
Show 5 removed
  • Investigational Site Number: 8400002 · Chapel Hill, United States
  • Investigational Site Number: 2500004 · Vandœuvre-lès-Nancy, France
  • Investigational Site Number: 8400013 · Harrisburg, United States
  • Investigative Site: 2500006 · Nice, France
  • Investigational Site Number: 2500003 · Toulouse, France
across 2 updates, Oct 2, 2026 – Nov 2, 2026
Enrollment
99 (estimated)→105 (actual)
Oct 9, 2026
Eligibility
2 inclusion criteria edited; 4 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedMust have active moderate-to-severe UC at screening as defined by a modified Mayo Score (mMS) of 5 to 9 (without the Physician Global Assessment (PGA), with a minimum Rectal Bleeding (RB) subscore ≥1, a minimum Stool Frequency (SF) subscore ≥1, mMES ≥2 confirmed by central reader, a minimum sum of all subscores of 5, and a minimum disease extent of 15 cm from the anal verge
  • EditedHistory of inadequate response to, loss of response to or intolerance to standard treatment with any of the following compounds: amino-salicylates, corticosteroids, methotrexate, azathioprine, or 6-mercaptopurine, or history of corticosteroid dependence (defined as an inability to successfully taper corticosteroids without recurrence of UC) AND history of no prior exposure to approved Advanced Therapies (ATs), such as a biologic agent used to treat UC or advanced small molecules used to treat UC
Exclusion criteria
  • EditedHistory of demyelinating disease (including myelitis), family history of demyelinating disease, or neurologic symptoms suggestive of demyelinating disease
  • EditedPositive (or indeterminate) Hepatitis B surface antigen (HBs Ag) or,
  • EditedPositive total Hepatitis B core antibody (anti-HBcHBcAB) confirmed by positive Hepatitis B Virus (HBV) Deoxyribonucleic acid (DNA) or,
  • ChangedBefore Positive Hepatitis C Virus (HCV) antibodyNow Positive Hepatitis C Virus (HCV) antibody confirmed by positive HCV Ribonucleic Acid (RNA) (participants with HCV antibody (HCVAb) and negative HCV RNA may be included).
Oct 2, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionProportion of participants who achieve clinical remission at the end of Week 16 by modified Mayo Score (mMS): how it is measured was reworded
Oct 2, 2026
Secondary outcomes
4 edited, 12 removed, 3 description edited
What changed in the outcomes
  • EditedProportion of participants who achieve endoscopicclinical response at Week 5216 by total MSTime frame: At Week 52 → At Week 16
  • EditedProportion of participants who achieve endoscopic remissionclinical response at Week 5216 by mMSTime frame: At Week 52 → At Week 16
  • EditedProportion of participants who achieve clinical remission by total Mayo Score (MS) at Week 52 by mMSTime frame: At Week 52
  • EditedSerum SAR442970brivekimig concentrationsTime frame: Up to end of study (approximately 164 weeks)
  • RemovedProportion of participants who achieve clinical response by total MS at Week 16Time frame: At Week 16
  • RemovedProportion of participants who achieve clinical response by total MS at Week 52Time frame: At Week 52
  • RemovedProportion of participants who achieve clinical response by mMS at Week 16Time frame: At Week 16
  • RemovedProportion of participants who achieve clinical response by mMS at Week 52Time frame: At Week 52
  • RemovedProportion of participants who achieve clinical remission by mMS at Week 52Time frame: At Week 52
  • RemovedChange from baseline in PRO-2 (Patient Reported Outcome) total score (SF and RB)Time frame: From Baseline to Week 16 and up to End of Study (approximately 164 weeks)
  • RemovedChange from baseline in mMS (SF, RB, and mMES)Time frame: From Baseline to Week 16 and up to End of Study (approximately 164 weeks)
  • RemovedChange from baseline in Partial Mayo Score (PMS) (SF, RB, and Physician's Global Assessment [PGA])Time frame: From Baseline to Week 16 and up to End of Study (approximately 164 weeks)
  • RemovedProportion of participants who achieve histological improvement by Original Geboes Score (OGS) to assess inflammation in UCTime frame: At Week 16
  • RemovedProportion of participants who achieve histological remission by Robarts Histopathology Index (RHI)Time frame: At Week 16
  • RemovedProportion of participants who achieve histological remission by OGS to assess inflammation in UCTime frame: At Week 16
  • RemovedProportion of participants who achieve Histologic Endoscopic Mucosal Improvement (HEMI)Time frame: At Week 16
  • DescriptionProportion of participants who achieve clinical remission by total Mayo Score (MS) at Week 16: how it is measured was reworded
  • DescriptionProportion of participants who achieve endoscopic improvement at Week 16: how it is measured was reworded
  • DescriptionProportion of participants who achieve endoscopic remission at Week 16: how it is measured was reworded
Oct 2, 2026
Title
A Study to Investigate the Efficacy and Safety of SAR442970Brivekimig in Adult Participants With Ulcerative Colitis
Oct 2, 2026
Show all 3 updates
  1. Nov 2, 2026
    6 sites added, 3 sites removed
    Show 6 added (2 United States, 1 Australia, 1 France, 1 Spain, 1 United Kingdom)
    • Investigational Site Number: 8400027 · Fairhope, United States
    • Investigational Site Number: 8400028 · Kansas City, United States
    • Investigational Site Number: 360002 · Murdoch, Australia
    • Investigational Site Number: 2500006 · Nice, France
    • Investigational Site Number: 7240003 · Barcelona, Spain
    • Investigational Site Number: 8260005 · Cambridge, United Kingdom
    Show 3 removed
    • Investigational Site Number: 8400013 · Harrisburg, United States
    • Investigative Site: 2500006 · Nice, France
    • Investigational Site Number: 2500003 · Toulouse, France
    + 1 other change: references
  2. Oct 9, 2026
    Enrollment 99 (estimated)→105 (actual)
    + 1 other change: verification date
  3. Oct 2, 2026
    Recruiting→Active, not recruiting
    1 site added, 2 sites removed
    Show site
    • Investigational Site Number: 2500007 · Montpellier, France
    Show 2 removed
    • Investigational Site Number: 8400002 · Chapel Hill, United States
    • Investigational Site Number: 2500004 · Vandœuvre-lès-Nancy, France
    Eligibility 2 inclusion criteria edited; 4 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedMust have active moderate-to-severe UC at screening as defined by a modified Mayo Score (mMS) of 5 to 9 (without the Physician Global Assessment (PGA), with a minimum Rectal Bleeding (RB) subscore ≥1, a minimum Stool Frequency (SF) subscore ≥1, mMES ≥2 confirmed by central reader, a minimum sum of all subscores of 5, and a minimum disease extent of 15 cm from the anal verge
    • EditedHistory of inadequate response to, loss of response to or intolerance to standard treatment with any of the following compounds: amino-salicylates, corticosteroids, methotrexate, azathioprine, or 6-mercaptopurine, or history of corticosteroid dependence (defined as an inability to successfully taper corticosteroids without recurrence of UC) AND history of no prior exposure to approved Advanced Therapies (ATs), such as a biologic agent used to treat UC or advanced small molecules used to treat UC
    Exclusion criteria
    • EditedHistory of demyelinating disease (including myelitis), family history of demyelinating disease, or neurologic symptoms suggestive of demyelinating disease
    • EditedPositive (or indeterminate) Hepatitis B surface antigen (HBs Ag) or,
    • EditedPositive total Hepatitis B core antibody (anti-HBcHBcAB) confirmed by positive Hepatitis B Virus (HBV) Deoxyribonucleic acid (DNA) or,
    • ChangedBefore Positive Hepatitis C Virus (HCV) antibodyNow Positive Hepatitis C Virus (HCV) antibody confirmed by positive HCV Ribonucleic Acid (RNA) (participants with HCV antibody (HCVAb) and negative HCV RNA may be included).
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionProportion of participants who achieve clinical remission at the end of Week 16 by modified Mayo Score (mMS): how it is measured was reworded
    Secondary outcomes 4 edited, 12 removed, 3 description edited
    What changed in the outcomes
    • EditedProportion of participants who achieve endoscopicclinical response at Week 5216 by total MSTime frame: At Week 52 → At Week 16
    • EditedProportion of participants who achieve endoscopic remissionclinical response at Week 5216 by mMSTime frame: At Week 52 → At Week 16
    • EditedProportion of participants who achieve clinical remission by total Mayo Score (MS) at Week 52 by mMSTime frame: At Week 52
    • EditedSerum SAR442970brivekimig concentrationsTime frame: Up to end of study (approximately 164 weeks)
    • RemovedProportion of participants who achieve clinical response by total MS at Week 16Time frame: At Week 16
    • RemovedProportion of participants who achieve clinical response by total MS at Week 52Time frame: At Week 52
    • RemovedProportion of participants who achieve clinical response by mMS at Week 16Time frame: At Week 16
    • RemovedProportion of participants who achieve clinical response by mMS at Week 52Time frame: At Week 52
    • RemovedProportion of participants who achieve clinical remission by mMS at Week 52Time frame: At Week 52
    • RemovedChange from baseline in PRO-2 (Patient Reported Outcome) total score (SF and RB)Time frame: From Baseline to Week 16 and up to End of Study (approximately 164 weeks)
    • RemovedChange from baseline in mMS (SF, RB, and mMES)Time frame: From Baseline to Week 16 and up to End of Study (approximately 164 weeks)
    • RemovedChange from baseline in Partial Mayo Score (PMS) (SF, RB, and Physician's Global Assessment [PGA])Time frame: From Baseline to Week 16 and up to End of Study (approximately 164 weeks)
    • RemovedProportion of participants who achieve histological improvement by Original Geboes Score (OGS) to assess inflammation in UCTime frame: At Week 16
    • RemovedProportion of participants who achieve histological remission by Robarts Histopathology Index (RHI)Time frame: At Week 16
    • RemovedProportion of participants who achieve histological remission by OGS to assess inflammation in UCTime frame: At Week 16
    • RemovedProportion of participants who achieve Histologic Endoscopic Mucosal Improvement (HEMI)Time frame: At Week 16
    • DescriptionProportion of participants who achieve clinical remission by total Mayo Score (MS) at Week 16: how it is measured was reworded
    • DescriptionProportion of participants who achieve endoscopic improvement at Week 16: how it is measured was reworded
    • DescriptionProportion of participants who achieve endoscopic remission at Week 16: how it is measured was reworded
    Title A Study to Investigate the Efficacy and Safety of SAR442970Brivekimig in Adult Participants With Ulcerative Colitis
    + 4 other changes: verification date, arm descriptions, contact details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06975722
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 16, 2025
Start date
Jul 7, 2025
Primary completion
Dec 17, 2026 (estimated)
Completion
Oct 17, 2029 (estimated)
Last update
Nov 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivekimig

Start the discussion